Data as of Dec 19
| +1.73 / +3.15%|
PTC Therapeutics, Inc. is a biopharmaceutical company, which is focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes. It's preclinical and discovery programs are focused on the development of new treatments for multiple therapeutic areas, including neuromuscular disease, oncology andinfectious disease. The company's lead product candidate ataluren is used for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation. PTC Therapeutics was founded by Allan S. Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
|Stuart W. Peltz||Chief Executive Officer & Director|
|Shane William Charles Kovacs||Chief Financial Officer|
|Neil Gregory Almstead||SVP-Research, Chemistry, Manufacturing & Controls|
|Robert Jay Spiegel||Chief Medical Officer|
|Mark Elliott Boulding||Secretary, Chief Legal Officer & Executive VP|